Please login to the form below

Not currently logged in
Email:
Password:

Diagnostic breath-test analysis developed

Oxford Medical Diagnostics has developed a technology that enables diagnostics for various illnesses through breath analysis

Oxford Medical Diagnostics (OMD), which was formed in August 2010, has developed a unique technology that enables rapid, accurate and low-cost diagnostics for various illnesses, including diabetes, through breath analysis.

The company is currently prototyping a non-invasive point-of-care (at patient) diagnostic instrument to detect diabetes types 1 and 2, through identifying acetone in the breath. There are currently no major direct competitors in this area, while alternative methods include blood analysis which can be both painful and inconvenient.

The company's management team includes the CEO, Dr Tony Marchington, who founded Oxford Molecular, which reached an FTSE 250 valuation of £475m. This spin-off counts as one of the most successful entities linked to the University of Oxford and its intellectual property company, Isis Innovation.

OMD maintains close links with the University of Oxford and academics around the world, while it holds three important patents in plasma emission spectroscopy (PES – spectral analysis of light generated from a gaseous sample through which a small electric arc is passed) and exclusive licences to two further major patents through the University of Oxford.

10th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics